Gallium gozetotide not checked

Novartis · Ga-PSMA-11

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
5 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Provided as PSMA-11 Kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide”In the company’s words, NCT05939414 on ClinicalTrials.gov
Tested for
Oligometastatic Prostate Cancer (OMPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).”In the company’s words, NCT05939414 on ClinicalTrials.gov
Other names
Ga-PSMA-11 · Locametz · Illuccix

Other drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

All 25 drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Coming up1

Changes2

Last 90 days

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 25 Apr 2028 An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 2Active, not recruiting 2 Dec 2024 A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 3Completed 23 Nov 2023 Study of Diagnostic Performance of [18F]CTT1057 in BCR
Phase 1/2Withdrawn 31 Mar 2030 Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
Phase 1Terminated 16 Oct 2026 NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Gallium gozetotide

Following is part of Solo: you see every change to Gallium gozetotide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in